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Abstract
Background: Endothelial progenitor cells play an important role in vascular wall repair. Patients with type 1 diabetes have
reduced levels of endothelial progenitor cells of which their functional capacity is impaired. Reduced nitric oxide bioavailability
and increased oxidative stress play a role in endothelial progenitor cell dysfunction in these patients. Folic acid, a B-vitamin with
anti-oxidant properties, may be able to improve endothelial progenitor cell function. In this study, we investigated the gene
expression profiles of endothelial progenitor cells from patients with type 1 diabetes compared to endothelial progenitor cells
from healthy subjects. Furthermore, we studied the effect of folic acid on gene expression profiles of endothelial progenitor cells
from patients with type 1 diabetes.
Methods: We used microarray analysis to investigate the gene expression profiles of endothelial progenitor cells from type 1
diabetes patients before (n = 11) and after a four week period of folic acid supplementation (n = 10) compared to the gene
expression profiles of endothelial progenitor cells from healthy subjects (n = 11). The probability of genes being differentially
expressed among the classes was computed using a random-variance t-test. A multivariate permutation test was used to identify
genes that were differentially expressed among the two classes. Functional classification of differentially expressed genes was
performed using the biological process ontology in the Gene Ontology database.
Results: Type 1 diabetes significantly modulated the expression of 1591 genes compared to healthy controls. These genes were
found to be involved in processes regulating development, cell communication, cell adhesion and localization. After folic acid
treatment, endothelial progenitor cell gene expression profiles from diabetic patients were similar to those from healthy
controls. Genes that were normalized by folic acid played a prominent role in development, such as the transcription factors
ID1 and MAFF. Few oxidative-stress related genes were affected by folic acid.
Conclusion: Folic acid normalizes endothelial progenitor cell gene expression profiles of patients with type 1 diabetes. Signaling
pathways modulated by folic acid may be potential therapeutic targets to improve endothelial progenitor cell function.
Published: 25 August 2009
Cardiovascular Diabetology 2009, 8:47 doi:10.1186/1475-2840-8-47
Received: 8 July 2009
Accepted: 25 August 2009
This article is available from: http://www.cardiab.com/content/8/1/47
© 2009 van Oostrom et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Cardiovascular Diabetology 2009, 8:47 http://www.cardiab.com/content/8/1/47
Page 2 of 11
(page number not for citation purposes)
Background
Diabetes mellitus (DM) is a major risk factor for micro-
and macrovascular complications[1,2] and is associated
with endothelial dysfunction, premature atherosclerosis
[3-5], and a reduced capability of neovascularization in
ischemic conditions[6]. Hyperglycemia increases the pro-
duction of superoxide (O2
-) and reduces the bioavailabil-
ity of nitric oxide (NO) resulting in the development of
endothelial dysfunction in diabetic patients[7,8]. Expo-
sure to oxidative stress induces a pro-inflammatory
response and increases endothelial cell apoptosis, which
leads to a disturbance in the endothelial monolayer. The
denuded vessel wall is highly pro-atherogenic, so fast
regeneration of the endothelium is essential to prevent
formation of atherosclerotic plaques[9,10].
Besides repair of the endothelial monolayer by adjacent
mature endothelial cells, circulating bone marrow-
derived endothelial progenitor cells (EPC) are also recog-
nized to play an important role in reendothelialization
[11-15]. Furthermore, studies have shown that ex vivo
expanded EPC can home to sites of ischemia, express
endothelial markers and improve neovascularization and
tissue regeneration [16-18]. In addition, clinical trials are
ongoing to evaluate the regenerative capacity of EPC in
patients with ischemic limb or heart disease[19]. Patients
with cardiovascular risk factors, such as type 1 or 2 DM,
have decreased numbers of EPC and these show impaired
functional capacity [20-24]. Mechanisms underlying
endothelial dysfunction, such as reduced NO bioavaila-
bility and increased oxidative stress also play a role in EPC
dysfunction in patients with DM[25,26].
Increasing NO bioavailability by improving endothelial
nitric oxide synthase (eNOS) function can be achieved by
folic acid (FA) supplementation. The active form of FA, 5-
methyltetrahydrofolate restores the function of uncou-
pled eNOS by increasing the availability of its cofactor tet-
rahydrobiopterin (BH4)[27]. Studies have shown that FA
supplementation restores endothelial function in patients
with coronary artery disease[28,29], hyperhomocysteine-
mia [30-32], hypercholesterolemia [33-35], and type 1
and 2 DM [36-38]. Recently, it was shown that cardiac
function can be preserved after ischemia in FA-treated
rats[39]. In addition, exogenous BH4 improves pre-exist-
ing advanced cardiac hypertrophy and fibrosis in
mice[40]. These studies[39,40] describe novel beneficial
effects of FA, suggesting that its therapeutic potential in
cardiovascular disease still remains to be fully elucidated.
At the molecular level, the effects of DM on EPC are not
well characterized. Although a role for oxidative stress in
modulating EPC number and function has been
implied[25,26], the effects of DM on EPC gene expression
remain unclear. Autologous progenitor cell-based therapy
may not reach its true potential in diabetic patients when
their own progenitor cells are impaired. Therefore, a likely
therapeutic strategy may be the modulation of EPC levels
and/or function. Increased understanding of the mecha-
nisms leading to the numerical and functional impair-
ment of EPC is necessary. In this study, we investigated the
gene expression profiles of EPC in DM type 1 (DM1)
patients compared to healthy subjects. Furthermore, we
show that FA can change the gene expression profiles of
EPC from DM1 patients to resemble those of healthy sub-
jects.
Methods
Subjects
Patients with DM1 (n = 20), diagnosed at least 1 year
before entering the study, were recruited from the outpa-
tient clinic of the Department of Internal Medicine of the
University Medical Centre Utrecht, The Netherlands.
Exclusion criteria were presence of manifest macrovascu-
lar disease, liver disease, homocysteine > 15 μmol/l, creat-
inine > 120 μmol/l and untreated thyroid disease. If
patients were being treated with vasoactive medication
(angiotensin converting enzyme inhibitors, angiotensin II
antagonists, statins, nonsteroidal anti-inflammatory
drugs (NSAIDs), FA or vitamins), treatment was stopped
at least 3 weeks before initiation of the study. Twenty age-
and gender-matched healthy subjects served as controls.
Cardiovascular risk was evaluated by a questionnaire and
clinical parameters such as weight, length and blood pres-
sure were measured.
Peripheral blood samples were collected from 20 patients
with DM1 and 20 age- and gender-matched healthy con-
trol subjects (CTR) at baseline. Patients with DM1 were
then treated for 4 weeks with FA (Ratiopharm) 5 mg/day
after which peripheral blood samples were collected again
(19 of the 20 patients). The study protocol was approved
by the Medical Ethical Committee of the University Med-
ical Centre Utrecht. All participants in the study gave their
written informed consent.
EPC Culture
Peripheral blood samples (90 ml) were collected in EDTA
tubes (Greiner Bio-One) and mononuclear cells (MNC)
were isolated using Ficoll density gradient centrifugation
(Ficoll-Paque Plus; GE Healthcare Bio-Sciences). MNC
were plated on human fibronectin (Becton Dickinson)-
coated six-well plates (Corning) at a density of 5 × 106
cells/ml of EGM-2 medium (Cambrex), supplemented
with 20% fetal calf serum (Invitrogen), 100 ng/ml recom-
binant VEGF-165 (R&D systems) and antibiotics (penicil-
lin 100 U/ml and streptomycin 100 μg/ml; Invitrogen).
Mononuclear cells were kept in a stove at 37°C, for 7 days,
allowing differentiation to EPC. At day 4, medium was
changed to wash away non-adherent cells. Cells used for
quantification were detached by using trypsin-EDTA (Inv-Cardiovascular Diabetology 2009, 8:47 http://www.cardiab.com/content/8/1/47
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itrogen) and gentle cell scraping, followed by counting on
a hemocytometer (Cell-Dyn 1800, Abbott Diagnostics).
EPC were cultured as previously described[41]. EPC phe-
notype of attaching cells was confirmed by the presence of
endothelial surface markers, the binding of Ulex Euro-
paeus Agglutinin-1 and the uptake of DiI-labeled
acetylated LDL.
Microarray Analysis
Total RNA was extracted from Trizol® (Invitrogen)-treated
EPC samples from 20 DM1 patients before and after treat-
ment with FA, and 20 age- and gender-matched healthy
control subjects according to manufacturer's instructions.
One sample from a FA treated DM1 patient was excluded
due to low total RNA yield. Chromosomal DNA was
removed from the samples by treatment with DNase I
(Amersham Biosciences). The concentration of the iso-
lated RNA was determined with the Nanodrop ND-1000
spectrophotometer (Nanodrop Technologies). The sam-
ples were independent isolates from single donors.
Microarray analysis was performed on EPC samples from
a subset of the patient population i.e. 11 DM1 patients, 10
DM1 patients after FA and 11 healthy controls. Double-
stranded cDNA was synthesized from 125 ng of total RNA
and in vitro transcription was performed to generate bioti-
nylated cRNA using the Illumina® TotalPrep™ RNA Ampli-
fication Kit (Ambion) according to the manufacturer's
instructions. From each sample, 850 ng of cRNA was
hybridized overnight at 55°C to Sentrix HumanRef-8
Expression BeadChips (Illumina), containing ~23000
genes. The following day the BeadChips were washed and
a signal was developed with streptavidin-Cy3 (Amersham
Biosciences). Chips were scanned with a BeadArray
Reader (Illumina).
Raw gene array bead summary intensities were extracted
using Beadstudio version 3.2 (Illumina) and quantile nor-
malized in R/Bioconductor. Normalized bead summary
intensities were imported in BRB-ArrayTools (developed
by Dr. Richard Simon and BRB-ArrayTools Development
Team) for further analysis. Microarray data are available at
http://www.ncbi.nlm.nih.gov/geo/, accession number
GSE17635.
Statistical Analysis
Differences in EPC numbers between patients with DM1
and healthy controls, and patients with DM1 before and
after FA treatment were determined by a Mann Whitney or
Wilcoxon signed rank test respectively. A p value < 0.05
was considered statistically significant.
The probability of genes being differentially expressed
among the classes was computed using a random-variance
t-test. The random-variance t-test is an improvement over
the standard separate t-test as it permits sharing informa-
tion among genes about within-class variation without
assuming that all genes have the same variance[42], A
multivariate permutation test was used to identify genes
that were differentially expressed among the two
classes[43,44]. The multivariate permutation test provides
90% confidence that the false discovery rate (FDR) is less
than 10%. The test statistics used are random variance t-
statistics for each gene[42]. Although t-statistics were
used, the multivariate permutation test is non-parametric
and does not require the assumption of Gaussian distribu-
tions. Gene clusters with similar gene expression patterns
across sample classes were identified by using hierarchical
clustering (Pearson 1 – correlation distances) on normal-
ized bead signal intensities. Functional classification of
differentially expressed genes was performed using the
biological process ontology in the Gene Ontology data-
base (GO; http://www.geneontology.org). Classification
was listed if a biological process term was significantly
overrepresented or underrepresented among differentially
expressed genes as compared to the Homo sapiens refer-
ence genome.
Results
Patient Characteristics
Patient characteristics are summarized in Table 1. The
group of diabetic patients is representative of a type 1 dia-
betic population without macrovascular complications.
Retinopathy was present in 4 patients. None of the
Table 1: Characteristics of patients with DM1. Data are mean ± 
SEM.
Type 1 diabetic patients (n = 20)
Age (years) 34.2 ± 6.4
Gender (male/female) 8/12
Body mass index (kg/m2) 22.8 ± 1.7
Blood pressure (mmHg)
Systolic 128 ± 13
Diastolic 83 ± 8
Duration of diabetes (years) 14.0 ± 6.6
Medication
Insulin 20/20
Antihypertensive drugs 2/20
NSAIDs 1/20
Statin 1/20
Oral anti conception 8/12
Folic acid 3/20
Current smoker 6/20
Glucose (mmol/l) 8.4 ± 3.6
HbA1c (%) 8.2 ± 0.6
Homocysteine (μmol/l) 8.2 ± 2.5
Total cholesterol (mmol/l) 4.3 ± 0.6
LDL (mmol/l) 2.3 ± 0.5
HDL (mmol/l) 1.6 ± 0.2
Triglycerides (mmol/l) 0.9 ± 0.3Cardiovascular Diabetology 2009, 8:47 http://www.cardiab.com/content/8/1/47
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patients had microalbuminuria. Antihypertensive drugs,
statins and FA supplementation were stopped at least 3
weeks before initiation of the study. Age and gender-
matched healthy controls did not significantly differ in
body mass index and blood pressure from patients with
DM1. FA treatment did not have any effect on the charac-
teristics.
Effect of DM1 on EPC Number
We assessed the number of EPC obtained after 7-day cul-
turing of peripheral blood MNC from patients with DM1
before (n = 20) and after 4 weeks (n = 19) of treatment
with FA and from healthy control subjects (n = 20). We
observed a 26% decrease in the mean number of EPC
from DM1 patients compared to healthy control subjects
(25575 ± 4891 versus 34375 ± 5065 EPC/106 MNC; p =
0.057). After FA treatment, the mean number of EPC
tended to increase slightly by 17% (25575 ± 4891 versus
29868 ± 3754 EPC/106 MNC; p = 0.14) (Figure 1). No sig-
nificant differences in EPC number were observed
between healthy controls and DM1 patients after FA
(34375 ± 5065 versus 29868 ± 3754 EPC/106 MNC; p =
0.37).
Differential Gene Expression in EPC from Patients With 
DM1 Before and After FA Treatment and Healthy Controls
Whole genome microarray analysis was performed to
compare gene expression profiles of EPC from patients
with DM1 before and after FA treatment and healthy con-
trols. At a FDR of 0.05, a total of 2170 genes were differ-
entially expressed between DM1 patients before and after
FA treatment and healthy controls. This set of genes was
used for hierarchical clustering analysis. The dendrogram
in Figure 2 demonstrates the close correlation of the gene
expression profiles of EPC from FA-treated DM1 patients
and healthy controls which are clustered together while
gene expression profiles of EPC from DM1 patients are
placed in a distinct group.
The result of the differential gene expression analysis is
summarized in Figure 3 with the Venn diagram depicting
the distribution of 2170 probe sets found to be differen-
tially expressed in EPC in at least 1 comparison at a FDR
of 0.05. 1591 genes are differentially expressed between
DM1 patients and healthy controls, and 1092 genes are
differentially expressed in DM1 patients before and after
FA. The intersect shows that 513 genes with differential
expression between healthy controls and DM1 are also
modulated by FA treatment. Gene expression profiles of
EPC from healthy controls and DM1 patients after FA
were very similar and pairwise comparison shows no dif-
ferentially expressed genes at a 0.05 FDR level.
Effect of DM1 on EPC number Figure 1
Effect of DM1 on EPC number. EPC number from dia-
betic patients before (DM1, n = 20) and after treatment with 
FA (DM1 + FA, n = 19) and from age- and gender-matched 
healthy control subjects (CTR, n = 20). Data are presented 
as mean ± SEM.
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Similarity of gene expression profiles of EPC between healthy  controls and FA-treated DM1 patients Figure 2
Similarity of gene expression profiles of EPC 
between healthy controls and FA-treated DM1 
patients. Unsupervised hierarchical clustering based on 
gene expression of EPC from DM1 patients before and after 
FA treatment and healthy controls. Clustering of conditions 
partitioned samples into 2 groups. The gene expression pro-
files of healthy controls (CTR) and FA-treated DM1 patients 
are clustered together as a distinct group, separated from 
the gene expression profiles of EPC from patients with DM1 
before FA-treatment.
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Classification of Differentially Expressed Genes in EPC of 
Patients With DM1 Compared to Healthy Controls
To investigate the effect of DM1 on EPC gene expression
on a more functional level, differentially regulated genes
in EPC of patients with DM1 compared to healthy con-
trols were classified into Gene Ontology (GO) terms
(Table 2). Fifty-five GO terms with a p value of less than
0.01 in the differentially expressed gene set were enriched
compared to a random gene set of equal size, resulting in
an enrichment including 'cell communication', 'develop-
mental process', 'localization', 'cell proliferation' and 'cell
adhesion'. 30% of the differentially regulated genes were
involved in cell communication, including members of
the desintegrin and metalloproteinase domain family
(upregulated HOXD9, ID1, NFATC3; downregulated
MAFF, HOXB8, HOXD8), interleukin family (upregulated
IL12RB1, IL12RB2, IL13, IL18, IL1RAP; downregulated
IL1RL1, IL9R), RAS GTPase superfamily (upregulated
RAB39B, RABL2A, RASAL1, RASAL2, and RASD2; down-
regulated RAB11B, RAB27A, RAB3B, RABL4, RASA1) and
TNF receptor family (downregulated TNFRSF-14, -17).
26% of the genes were categorized into the GO term
'developmental process', including members of the
fibroblast growth factors (upregulated FGF3, FGF11),
transcription regulators (upregulated HOXD9, ID1,
NFATC3; downregulated MAFF, HOXB8, HOXD8), and
members of the wingless-type (Wnt) pathway (upregu-
lated FRZB, WNT10B, WNT11).
Cell adhesion plays an important role in progenitor cell
biology and has previously been shown to be impaired in
EPC from DM patients[24]. We therefore examined genes
that were affected in our DM1 population and could
potentially have a role in EPC adhesion. We found that
members of the protocadherin family involved in cal-
cium-dependent cell adhesion (upregulated PCDH8,
PCDHB8, PCDHB9, PCDHGA4, PCDHGB3; downregu-
lated PCDHA8, PCDHGA10, PCDHGA3, PCDHGA7,
PCDHGB2), structural proteins (upregulated SPON1,
COL13A1; downregulated COL21A1) and integrin-
related binding proteins (upregulated ADAM22, IBSP,
ITGB1; downregulated ADAM2) were included in the cat-
egory 'cell adhesion'.
We also examined the genes categorized into GO terms
'response to stress' and 'response to hypoxia' because of
the known effect of diabetes on oxidative stress-related
signaling. These genes included dual oxidase 2 (DUOX2),
which is a NADPH oxidase and has the capacity to gener-
ate superoxide, nitric oxide synthase 2A (NOS2A), which
can produce nitric oxide, thioredoxin reductase 2
(TXNRD2), a key enzyme in the regulation of the intracel-
lular redox balance, lactoperoxidase (LPO) and NADPH
oxidase organizer 1 (NOXO1), which is involved in reac-
tive oxygen species production, all of which were upregu-
lated in EPC from patients with DM1.
FA Normalizes Changes in Gene Expression in EPC From 
Patients With DM1
Interestingly, 513 genes that were differentially expressed
between healthy controls and patients with DM1 were
normalized by FA treatment. Genes with this expression
pattern are visualized in the heat map depicted in Figure
4. 390 genes were upregulated (cluster 1) and 123 genes
(cluster 2) were downregulated in DM1 (for the complete
list of gene names, see Additional file 1) and the expres-
sion of these genes was normalized to healthy control lev-
els after FA treatment.
To more closely examine the observed effects of FA on dia-
betic EPC gene expression, we classified the 513 genes
into Gene Ontology terms (Figure 5). Fourteen terms in
the list had a p value of less than 0.01. Strikingly, many of
these processes are related to development, indicating a
major effect of FA on developmental processes. Gene
expression of fibroblast growth factor 3 (FGF3), transcrip-
tional regulators (HOXD8, HOXD9, ID1, MAFF), and
members of the Wnt pathway (FRZB, WNT11) was signif-
icantly different between DM1 and healthy controls and
normalized by FA. We also examined the category 'cell
adhesion', which was modulated by DM1 and found that
FA regulated several members of the protocadherin family
(PCDH8, PCDHB8, PCDHB9, PCDHGA10, PCDHGA4,
PCDHGB3), structural protein collagen type XIII alpha 1
A Venn diagram depicting differential gene expression Figure 3
A Venn diagram depicting differential gene expres-
sion. The distribution is represented of 2170 probe sets 
found to be differentially expressed in EPC in at least 1 com-
parison (DM1, DM1 + FA, CTR) at a FDR of 0.05.
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Table 2: Classification of differentially expressed genes between healthy controls and DM1 patients according to gene ontology (GO) 
terms with a p value < 0.01.
Term Category % of genes in category p value
GO:0032501 multicellular organismal process 32,02 9,28E-09
GO:0007275 multicellular organismal development 21,45 1,93E-07
GO:0048856 anatomical structure development 19,24 3,11E-06
GO:0007267 cell-cell signaling 7,89 5,22E-06
GO:0006812 cation transport 6,94 5,94E-06
GO:0048731 system development 16,25 6,22E-06
GO:0032502 developmental process 26,18 1,94E-05
GO:0006811 ion transport 8,99 2,27E-05
GO:0030001 metal ion transport 5,52 7,57E-05
GO:0009605 response to external stimulus 7,10 1,11E-04
GO:0015672 monovalent inorganic cation transport 4,57 1,19E-04
GO:0048513 organ development 11,83 1,56E-04
GO:0006813 potassium ion transport 2,84 2,01E-04
GO:0051179 localization 24,29 4,04E-04
GO:0006091 generation of precursor metabolites and energy 6,78 4,90E-04
GO:0007167 enzyme linked receptor protein signaling pathway 3,79 5,36E-04
GO:0003012 muscle system process 2,68 6,04E-04
GO:0006936 muscle contraction 2,68 6,04E-04
GO:0019226 transmission of nerve impulse 4,26 7,76E-04
GO:0007188 G-protein signaling, coupled to cAMP nucleotide second messenger 1,74 1,35E-03
GO:0008283 cell proliferation 7,57 1,65E-03
GO:0006950 response to stress 9,62 1,76E-03
GO:0008284 positive regulation of cell proliferation 3,15 1,97E-03
GO:0009611 response to wounding 4,73 1,99E-03
GO:0007189 G-protein signaling, adenylate cyclase activating pathway 1,10 2,11E-03
GO:0019933 cAMP-mediated signaling 1,74 2,27E-03
GO:0006954 inflammatory response 3,63 2,53E-03
GO:0007154 cell communication 29,50 2,75E-03
GO:0007155 cell adhesion 7,26 2,76E-03
GO:0022610 biological adhesion 7,26 2,76E-03
GO:0006928 cell motility 4,57 2,81E-03
GO:0051674 localization of cell 4,57 2,81E-03
GO:0030041 actin filament polymerization 0,95 3,08E-03
GO:0044262 cellular carbohydrate metabolic process 3,94 3,72E-03
GO:0007156 homophilic cell adhesion 2,21 3,85E-03
GO:0006952 defense response 5,68 4,07E-03
GO:0031279 regulation of cyclase activity 1,10 4,16E-03
GO:0051339 regulation of lyase activity 1,10 4,16E-03
GO:0007187 G-protein signaling, coupled to cyclic nucleotide second messenger 1,89 4,78E-03
GO:0016051 carbohydrate biosynthetic process 1,89 4,78E-03
GO:0019317 fucose catabolic process 0,63 5,29E-03
GO:0042355 L-fucose catabolic process 0,63 5,29E-03
GO:0007173 epidermal growth factor receptor signaling pathway 0,95 5,72E-03
GO:0007268 synaptic transmission 3,47 5,92E-03
GO:0001501 skeletal development 2,84 6,00E-03
GO:0008154 actin polymerization and/or depolymerization 1,26 6,04E-03
GO:0007610 behavior 3,63 6,90E-03
GO:0007169 transmembrane receptor protein tyrosine kinase signaling pathway 2,52 6,99E-03
GO:0019935 cyclic-nucleotide-mediated signaling 1,89 7,81E-03
GO:0003008 system process 11,67 8,19E-03
GO:0007626 locomotory behavior 2,52 8,37E-03
GO:0042127 regulation of cell proliferation 4,89 8,47E-03
GO:0001666 response to hypoxia 1,10 9,08E-03
GO:0042354 L-fucose metabolic process 0,63 9,17E-03
GO:0043085 positive regulation of catalytic activity 2,84 9,54E-03Cardiovascular Diabetology 2009, 8:47 http://www.cardiab.com/content/8/1/47
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Heat map display of genes that are normalized by FA in EPC of DM1 patients Figure 4
Heat map display of genes that are normalized by FA in EPC of DM1 patients. Visualization of mean-centered and 
normalized gene expression patterns of the 513 intersect genes with differential expression between healthy controls (CTR) 
and DM1 patients that are normalized by FA treatment. The relative levels of gene expression are depicted with a color scale, 
where green represents the lowest and red the highest level of expression. Two main clusters of genes can be clearly identified 
as marked by an asterisk.
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(COL13A1) and integrin beta 1 (ITGB1). Furthermore,
genes involved in G protein signaling including guanine
nucleotide binding proteins (GNAL, GNAQ), cortistatin
(CORT), gamma-aminobutyric acid B receptor 1
(GABBR1), gastric inhibitory polypeptide receptor (GIPR)
and parathyroid hormone-like hormone (PTHLH) were
regulated by FA. Four oxidative stress-related genes
(DUOX2, NOS2A, NOXO1 and LPO) which were differ-
entially expressed between DM1 and healthy controls
returned to control levels by FA.
Discussion
In this study we investigated the effects of FA on the tran-
scriptome of EPC from patients with DM1. We found that
DM1, compared to healthy controls, modulates the
expression of 1591 genes which are mainly involved in
cell communication, development, localization, cell pro-
liferation and cell adhesion. FA treatment for 4 weeks in
patients with DM1 leads to the normalization of the gene
expression of 513 of the 1591 genes. In particular, FA reg-
ulated genes that are involved in development, cell adhe-
sion and G protein signaling.
This study describes differential gene expression profiling
of EPC between patients with DM1 and healthy controls.
Importantly, in order to be able to improve impaired
numerical and functional capacity of EPC, identification
of genes that are affected by DM1 is required. We observed
an effect of DM1 on members of the desintegrin and met-
alloproteinase domain family (ADAM17, ADAM22,
ADAMTS14 and ADAMTS18) involved in cell communi-
cation. ADAM22, a membrane spanning protein, is one of
the most strongly upregulated genes in DM1 compared to
healthy controls. Little is known about this member of the
ADAM family, however, it has been shown that other
members such as ADAM17 can potentially play a role in
angiogenesis and cytokine biology in inflammatory proc-
esses[45,46]. Of note, ADAM17, also known as TNF-α
converting enzyme which is important in processing and
release of TNF-α from the cell membrane, was signifi-
cantly upregulated in EPC of DM1 patients[45,46].
Genes that also play a role in cell communication and
development are members of the TNF receptor family
(TNFRSF-14, and -17). TNFRSF-14 was significantly
downregulated in EPC of DM1 patients compared to
healthy controls. It has been described that this receptor
can play a dual role in regulating T cell immune responses
depending on ligand receptor interaction. Knockout ani-
mals are more susceptible to developing autoimmune dis-
eases[47], and T cell survival depends on receptor
activation[48]. In contrast, the receptor has been impli-
cated to play a role in inflammatory diseases such as rheu-
matoid arthritis[49,50] and atherosclerosis[51]. So far, no
studies have reported TNFRSF-14 expression in EPC,
therefore it remains to be investigated what its potential
role could be in EPC function.
A pie chart representing classification of 513 genes into Gene Ontology terms Figure 5
A pie chart representing classification of 513 genes into Gene Ontology terms. Biological processes, defined by 
genes that are normalized by FA treatment in EPC from patients with DM1, with a p value < 0.01 are listed.
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Other groups have performed microarray analysis on cir-
culating cells from patients with DM1, in particular
monocytes[52] and peripheral blood mononuclear
cells[53]. As EPC are cultured from the peripheral blood
mononuclear cell fraction and have been previously
described as a monocyte-like cell[54], some overlap in
gene expression between the different cell types can be
expected. Interestingly, similar expression patterns were
seen in EPC from DM1 patients in our study, and mono-
cytes and peripheral blood mononuclear cells from DM1
patients in the other studies[52,53], for splicing factor,
arginine/serine rich 15 (SFRS15), cell division cycle 42
(CDC42), interleukin 6 (IL6), heat shock 70 kDa protein
1A (HSPA1A), and chemokine ligand 20 (CCL20).
As expected, DM1 affected oxidative stress-related proc-
esses in comparison with healthy controls. In particular,
we found that expression of DUOX2, NOS2A, TXNRD2,
LPO and NOXO1 was upregulated in DM1 patients. FA
exerts protective anti-oxidant effects and has shown to
improve endothelial function in patients with cardiovas-
cular disease [28-38], In our study, we expected an effect
of FA treatment on the expression of oxidative stress-
related genes in EPC. FA indeed regulated expression of
DUOX2, NOS2A, NOXO1 and LPO. Unexpectedly, we
identified a striking effect of FA on genes involved in
developmental processes, cell adhesion and G protein sig-
naling. Inhibitor of differentiation 1 (ID1) was upregu-
lated in DM1 and normalized by FA. ID1 is a basic helix-
loop-helix transcription factor that lacks a DNA binding
domain. Through its ability to bind to the ubiquitously
expressed E protein family of basic helix-loop-helix tran-
scription factors, it can inhibit their binding to target
DNA. This important function of Id proteins confers a
central role in the regulation of gene expression and hence
cellular differentiation and proliferation[55,56]. Interest-
ingly, Id knockout mice show a complete loss of EPC in
the peripheral blood, which is correlated with a block in
tumor neovascularization and delayed tumor growth[57].
V-maf musculoaponeurotic fibrosarcoma oncogene
homolog F (MAFF) is a transcription factor that was
downregulated in DM1 and normalized by FA. Although
little is known about the functional role of MAFF in health
and disease, some studies have shown that it plays a role
in the cellular stress response. MAFF can bind to Nrf2, a
transcription factor that activates the expression of genes
with anti-oxidant response elements in their promot-
ers[58,59]. This is the first time that MAFF has been
described in association with DM1.
Moens et al[40] recently showed that exogenous BH4
could reverse pre-existing cardiac fibrosis and hypertro-
phy in mice. A microarray analysis was performed to iden-
tify genes that are regulated by BH4 in comparison to
another anti-oxidant approach (Tempol). It was reported
that BH4 had an effect on expression of ATP- and meta-
bolic and G protein signaling-regulated genes. This indi-
cates that FA may possess a more general modifying role
in pathological processes besides its known capacity to
restore NOS coupling.
We observed a decrease in EPC number in patients with
DM1 compared to healthy controls consistent with other
reports[21,24]. Treatment with FA only corrected for a
small part the number of EPC in patients with DM1 which
might be through the observed effect on ID1, modulating
differentiation and proliferation, or apoptosis[60].
Further research will be needed to more closely investigate
the individual role that the genes present in the set of FA-
regulated genes in EPC function. Signaling pathways
modulated by folic acid may be potential therapeutic tar-
gets to improve endothelial progenitor cell function.
Conclusion
This study employed genome-wide profiling to elucidate
the effect of DM1 and the response to FA on EPC gene
expression. We observed a remarkable effect of FA on gene
expression, resulting in normalization of EPC from DM1
patients to resemble those of healthy controls.
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